An Alzheimer’s Antibiotic Receives Initial Funding
Alzheimer’s disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field, according to a posting today on FierceBiotech. The healthy sum comes after the company completed an early safety study of its [...]